{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"The need for additional immunosuppressive treatment with agents other than those used for prophylaxis, the reasons for their administration (acute GVHD, chronic GVHD, or other reasons) and the duration of its administration will be determined. Patients will be monitored to determine the duration of systemic immunosuppressive treatment. Primary and secondary treatment of acute GVHD and withdrawal of systemic immunosuppressive treatment will be assessed with the use of cumulative incidence plots.","groups":[{"description":"PREPARATIVE REGIMEN: Patients receive TBI BID on days -4 or -3 to -1. Some patients also receive fludarabine IV daily on days -5 to -2 and busulfan IV over 3 hours QD or over 2 hours every 6 hours on days -5 to -2. Patients may also undergo CNS prophylaxis, testicular irradiation, and/or involved field irradiation as per standard practice.\n\nTRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0 per standard practice.\n\nGVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 1-2 hours on days 3-4. Patients also receive cyclosporine IV every 12 hours or every 8 hours beginning on day 5 with taper on days 56-126.\n\ncyclophosphamide: Given IV\n\ncyclosporine: Given IV\n\nperipheral blood stem cell transplantation: Undergo allogeneic PBSCT\n\ntotal-body irradiation: Undergo TBI\n\nfludarabine phosphate: Given IV\n\nbusulfan: Given IV\n\nallogeneic hematopoietic stem cell transplantation: Undergo allogeneic PBSCT","id":"OG000","title":"Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis)"}],"populationDescription":"This data was not collected.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Duration of Systemic Immunosuppressive Treatment","type":"SECONDARY"}